在对MET调节瘤的初步Vebreltinib第二期试验中,Apollomics报告了43%的ORR. Apollomics reports 43% ORR in preliminary vebreltinib Phase 2 trial for Met dysregulation tumors.

临床生物制药公司Apollomics报告了其用于治疗各种瘤的vebreltinib计划的有希望的初步结果,其中包括在SPARTA第二阶段临床试验中,对非CNS MET融合固体瘤的ORR为43%. Apollomics, a late-stage clinical biopharmaceutical company, reported promising preliminary results from their vebreltinib program for treating various tumors with Met dysregulation, including 43% ORR in SPARTA Phase 2 clinical trial for non-CNS MET fusion solid tumors. 该公司计划对NSCLC病人进行MET扩增登记。 The company plans to enroll NSCLC patients with MET amplification. 截至2024年6月30日,现金为25.9百万美元,他们有通向2025年Q3的现金跑道。 With $25.9M cash as of June 30, 2024, they have a cash runway into Q3 2025.

文章

GlobeNewswire

TMCnet

Market Screener

-- 显示更少 --

延伸阅读

相关故事